Genfit S.A. (GNFT.PA)

EUR 3.5

(2.04%)

Market Cap (In EUR)

174.26 Million

Revenue (In EUR)

28.56 Million

Net Income (In EUR)

-28.89 Million

Avg. Volume

190.1 Thousand

Currency
EUR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
3.025-5.86
PE
-
EPS
-
Beta Value
1.122
ISIN
FR0004163111
CUSIP
F43738107
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. M. Pascal Prigent
Employee Count
-
Website
https://www.genfit.com
Ipo Date
2006-12-19
Details
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.